Evaluating the Bioequivalence of Antibody–Drug Conjugates - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Evaluating the Bioequivalence of Antibody–Drug Conjugates
The authors discuss the analytical methods and related testing for bioequivalence studies of ADCs. This article is part of a special issue on analytical technology.

Pharmaceutical Technology
pp. s22-s27


1. T.T. Hansel, et al., Nature Rev. Drug Discov. 9 (4), 325–338 (2010).

2. D.R. Mould and K.R.D. Sweeney, Curr. Opin. in Drug Discov. Devel. 10, (1), 84–96 (2007).

3. Genentech, "Herceptin (trastuzumab) Intravenous Infusion, Full Prescribing Information" (South San Francisco, CA), http://www.gene.com/gene/products/information/oncology/herceptin/, accessed Oct. 10, 2011.

4. G.D. Lewis Phillips et al., Cancer Res. 68 (22), 9280–9290 (2008).

5. A. Beck, Discov. Med. 10 (53), 329–339 (2010).

6. I.E. Krop et al., J. Clinical Oncology 28 (16), 2698–2704 (2010).

7. H.A. Buris et al., et al. J. Clinical Oncology 29 (4), 398–405 (2011).

8. FDA, "FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from US Market," Press Release (Rockville, MD, June 21, 2010, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216448.htm, accessed Oct. 10, 2011.

9. EMA, Procedure No. EMEA/H/C/000705, EMEA/HMP/5130/2008 "Refusal Assessment Report for Mylotarg"(London, 2008).

10. P. Van Arnum, Pharm. Technol. 32 (6), 54–58 (2008).

11. A. Beck, T. Wurch, J.M. Reichert, Landes Biosci. 3 (2), 111–132 (2011).

12. A. Beck, P. Senter, and R. Chari, Landes Biosci. 3 (4) 331–337 (2011).

13. FDA, "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use" (Rockville, MD, Feb. 1997).

14. F. Ehmann, presentation at the GCC Workshop on Similar Biological Medicinal Products (Riyadh, Saudi Arabia, Apr. 19–20, 2011).

15. EMA, EMA/CHMP/BMWP/86289/2010, Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use (London, 2010).

16. Biophoenix, "Biosimilars, Biogenerics and Follow-on Biologics (Informa, UK 2007), http://www.scripintelligence.com/multimedia/archive/00000/BS1342_117a.pdf accessed Oct. 10, 2011.

17. A.G. Polson et al., Blood 110 (2), 616–623 (2007).

18. K. Anderson, presentation at the National Biotechnology Conference (San Francisco, 2011).

19. R.P. Lyon et al., presentation at the 101st Annual American Association for Cancer Research Meeting (Washington DC, 2010).

20. FDA, Guidance for Industry Safety Testing of Drug Metabolites (Rockville, MD, Feb. 2008).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here